Abstract
Summary
The Discovery Stage Partnering Agreements in Biopharma report provides
comprehensive understanding and unprecedented access to the discovery stage
partnering agreements entered into by the worlds leading biopharma companies.
- Discovery stage payment terms
- Discovery stage partnering contract documents
- Discovery stage partnering agreement terms
- Discovery stage partnering agreement structure
- Top discovery deals by value
- Most active discovery stage dealmakers
- plus much more
Description
The Discovery Stage Partnering Agreements in Biopharma report detailed
understanding and analysis of how and why companies enter discovery stage
licensing/business development and other forms of partnering arrangement.
The report provides a detailed understanding and analysis of how and why
companies enter discovery stage licensing/business development and other forms
of partnering arrangement.
The focus of the report is on partnerships for discovery technologies and
discovery stage compounds where partners have joined forces to exploit these
early stage opportunities. This is the earliest stage of partnering undertaken
by commercial entities with the objective of utilizing discovery technologies
to identify promising drug candidates.
The report provides access to average discovery stage deal payment terms as
announced between the parties. This data provides useful insight into the
average and range of payments for upfront, milestone and royalty payments
agreed for discovery stage deals.
This report contains over 1000 links to online copies of actual discovery
stage contract documents as submitted to the Securities Exchange Commission by
biopharma companies and their partners.
The initial chapters of this report provide an orientation of discovery stage
dealmaking and business activities. Chapter 1 provides an introduction to the
report, whilst chapter 2 provides an analysis of the trends in discovery stage
partnering as well as a discussion on the merits and attributes of dealmaking
at the discovery stage of development.
Chapter 3 provides an overview of the structure of discovery stage partnering
deal contracts. The chapter includes numerous case studies to enable
understanding of discovery stage partnering deals.
Chapter 4 provides a review of the leading discovery stage partnering deals
since 2000. Deals are listed by headline value, signed by bigpharma, most
active bigpharma, and most active of all biopharma companies. Where the deal
has an agreement contract published at the SEC a link provides online access
to the contract.
Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies
with a brief summary followed by a comprehensive listing of discovery stage
contract documents available in the public domain. Each deal title links via
Weblink to an online version of the actual contract document, providing easy
access to each contract document on demand.
Chapter 6 provides a comprehensive listing of all discovery stage agreement
contracts since 2003 available in the public domain, respectively. Each
chapter is organized by A-Z, therapeutic area, and deal type. Each deal title
links via Weblink to an online version of the actual contract document,
providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the
trends and activities in discovery stage dealmaking since 2000.
In conclusion, this report provides everything a prospective dealmaker needs
to know about discovery stage partnering, enabling thorough learning,
education and due diligence prior and during the discovery stage dealmaking
process.
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in discovery stage dealmaking
- 2.1. Introduction
- 2.2. Difference between discovery technologies and discovery compound deals
- 2.2.1. Trends in discovery stage deals since 2000
- 2.2.2. Attributes of discovery stage deals
- 2.3. Reasons for entering into discovery stage partnering deals
- 2.3.1. Licensors reasons for entering discovery stage deals
- 2.3.2. Licensees reasons for entering discovery stage deals
- 2.4. Components of discovery stage deals
- 2.5. Therapeutic focus of discovery stage deals
- 2.5.1. Oncology discovery dealmaking
- 2.5.2. CNS discovery dealmaking
- 2.5.3. Infectious discovery dealmaking
- 2.5.4. Autoimmune/Inflammatory discovery dealmaking
- 2.6. Technology focus of discovery deals
- 2.7. The future of discovery stage partnering deals
Chapter 3 - Overview of discovery stage deal structure
- 3.1. Introduction
- 3.2. The anatomy of a discovery stage deal
- 3.2.1. Example discovery stage agreements
- 3.2.1.a. Case study 1: Celgene - Array Biopharma - September 2007
- 3.2.1.b. Case study 2: GlaxoSmithKline - Targacept - July 2007
- 3.3. Typical discovery stage payment terms
- 3.3.1. Headline deal values
- 3.3.2. Upfront payments
- 3.3.3. Milestone payments
- 3.3.4. Royalties
Chapter 4 - Leading discovery stage deals
- 4.1. Introduction
- 4.2. Top discovery stage deals by value
- 4.3. Top discovery stage deals signed by bigpharma
- 4.4. Most active discovery stage dealmakers
- 4.5. Bigpharma discovery stage deal activity
Chapter 5 - Bigpharma discovery stage partnering agreements
- 7.1. Introduction
- 7.2. How to use discovery stage partnering agreements
- 7.3. Company discovery stage partnering agreement listings
- Abbott
- Actavis
- Alcon Labs
- Allergan
- Amgen
- Astellas
- AstraZeneca
- Barr Pharmaceuticals
- Baxter International
- Bayer
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Chugai
- CSL
- Daiichi Sankyo
- Eisai
- Eli Lilly
- Forest Laboratories
- Genentech
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- King
- Lundbeck
- Menarini
- Merck & Co
- Merck - Serono KGaA
- Mitsubishi
- Mundipharma
- Novartis AG
- Novo Nordisk
- Nycomed Pharma
- Otsuka
- Pfizer
- Procter & Gamble
- Ratiopharm
- Roche
- Sanofi-Aventis
- Schering Plough
- Servier
- Shire
- Solvay
- Stada
- Takeda
- Teva
- UCB
- Watson
- Wyeth
Chapter 6 - Discovery partnering agreement directory 2003-early 2008
- 6.1. Introduction
- 6.2. Company A-Z
- 6.3. By therapy area
- Accident/Hospital/Trauma
- Blood/Lymphatic System
- Cardiovascular
- Central nervous System
- Dermatology
- Gastrointestinal
- Genetic
- Genitourinary
- Autoimmune/Inflammatory
- Infection
- Metabolism
- Musculoskeletal
- Oncology
- Respiratory
- Sensory Organ / Oral Health
- Delivery
- 6.4. By deal type
- Collaborative R&D
- Co-development
- Co-marketing
- Co-promotion
- Development
- Distribution
- Joint venture
- Licensing
- M&A
- Manufacturing
- Marketing
- Promotion
- Research
- Supply
Appendices
- Appendix 1 - Discovery stage partnering references
- Appendix 2 - Resources
- Appendix 3 - Deal type definitions
- Appendix 3 - Deal type definitions
- Appendix 4 - Example discovery stage partnering contract
- About CurrentPartnering
- Recent report titles from CurrentPartnering
- Order Form - Reports
- Order form - Company Dealmaking Profiles
Table of figures
- Figure 1: Definition of discovery technology and discovery compound
dealmaking
- Figure 2: Trends in discovery stage deal announcements, 2000-2007
- Figure 3: Frequency of deal components in discovery stage deals - 2003 to
mid2008
- Figure 4: Discovery stage deals by therapy focus - 2003 - mid2008
- Figure 5: Frequency of oncology discovery dealmaking 2003-mid2008
- Figure 6: Primary discovery stage oncology dealmakers
- Figure 7: Frequency of CNS discovery dealmaking 2003-mid2008
- Figure 8: Primary discovery stage CNS dealmakers
- Figure 9: Frequency of infectious discovery dealmaking 2003-mid2008
- Figure 10: Primary discovery stage infectious dealmakers
- Figure 11: Frequency of autoimmune/inflammatory discovery dealmaking
2003-mid2008
- Figure 12: Primary discovery stage autoimmune/inflammatory dealmakers
- Figure 13: Technology focus for discovery deals 2003-mid2008
- Figure 14: Components of the discovery deal structure
- Figure 15: Discovery stage average payment terms
- Figure 16: Top discovery stage deals by value since 2003
- Figure 17: Bigpharma - top 50 - discovery stage deals since 2003
- Figure 18: Most active discovery stage dealmakers 2003-mid 2008
- Figure 19: Bigpharma - top 50 - discovery stage deals since 2003
- Figure 20: Online partnering resources
- Figure 21: Deal type definitions
- Figure 22: Partnering agreement between Dart Therapeutics and CombinatoRx
- November 2007
| 
